MedTrace Logo

Prediabetes Management

NCT05531838 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2022-09-08

No results posted yet for this study

Summary

Systematically screen the high-risk population of diabetes in Xinqiao district to understand the characteristics of early glucose metabolism changes and pancreatic islet function changes in patients with pre diabetes. Relying on MMC platform and combined with CGM therapeutic monitoring technology to standardize the management of patients with prediabetes, it is expected that the annual conversion rate of diabetes in patients with prediabetes will be 8% (according to the literature, if the pre diabetes population is not intervened, the annual conversion rate of diabetes will be about 14%), which will move forward the management of diabetes and create a new mode of pre diabetes management.

Conditions

  • PreDiabetes
  • Metabolic Management Center
  • Continuous Glucose Monitoring

Interventions

DEVICE

Fu Lishan instant sense hospital dynamic glucose monitoring system

Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2023-10-30
Completion
2023-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05531838 on ClinicalTrials.gov